Showing 1381-1390 of 5603 results for "".
Clinical Evidence: Insights From Early Trials of CDH6-Targeted Therapies
https://reachmd.com/programs/cme/clinical-evidence-insights-from-early-trials-of-cdh6-targeted-therapies/37669/CDH6 in Focus: Advancing Biomarker-Driven Strategies for Platinum-Resistant Ovarian CancerSafety, Clinical Integration, and the Emerging Fifth Pillar in HF Practice
https://reachmd.com/programs/cme/safety-clinical-integration-and-the-emerging-fifth-pillar-in-hf-practice/54635/Drs. Bauersachs, Butler & Lam discuss persistent residual risk in HFrEF, the use of sGC stimulators to reduce risk, and supporting evidence for this approach.First-Line Management of HR+/HER2-Low Breast Cancer With Brain Metastases
https://reachmd.com/programs/cme/first-line-management-of-hrher2-low-breast-cancer-with-brain-metastases/56519/Apply clinical evidence and multidisciplinary strategies to select and sequence systemic and local therapies for brain metastases in breast and lung cancer.Modern Obstructive HCM Care: From Unmet Needs to Individualized Myosin Inhibitor Therapy
https://reachmd.com/programs/cme/modern-obstructive-hcm-care-from-unmet-needs-to-individualized-myosin-inhibitor-therapy/56979/Explore how cardiac myosin inhibitors are reshaping obstructive HCM management, from unmet needs to individualized, evidence-based treatment.Beyond the Joint: Cross-Specialty Solutions for Advancing TGCT Patient Care
https://reachmd.com/programs/cme/beyond-the-joint-cross-specialty-solutions-for-advancing-tgct-patient-care/36596/Explore TGCT recognition, clinical evidence, treatment strategies, and management of adverse events with CSF1R inhibitors in an interdisciplinary context.Spotlight on Asia-Pacific: Practice Beyond Borders
https://reachmd.com/programs/cme/spotlight-on-asia-pacific-practice-beyond-borders/39810/Examine evolving global strategies for treating patients with HR+/HER2- mBC, integrating biomarker-driven therapy, clinical evidence, and toxicity management.Doublet or Triplet? A Case-Based Debate in First-Line Choices for HR+/HER2- mBC
https://reachmd.com/programs/cme/doublet-or-triplet-a-case-based-debate-in-first-line-choices-for-hrher2-mbc/39806/Examine evolving global strategies for treating patients with HR+/HER2- mBC, integrating biomarker-driven therapy, clinical evidence, and toxicity management.A Q-Challenge™ Replay: Advancing Precision Diagnosis and Treatment Strategies in Acromegaly
https://reachmd.com/programs/cme/a-q-challengetm-replay-advancing-precision-diagnosis-and-treatment-strategies-in-acromegaly/49278/Apply acromegaly diagnostic and treatment strategies through interactive, case-based Q-Challenge scenarios in a replay of an expert-led session from AACE 2026.Seeing the Invisible: Radiologic Precision to Enable Early Intervention in Bronchiectasis
https://reachmd.com/programs/cme/seeing-the-invisible-radiologic-precision-to-enable-early-intervention-in-bronchiectasis/56384/Join our experts in this engaging broadcast replay and improve your ability to differentiate the radiologic patterns of bronchiectasis from other lung diseases.IBD Care Reimagined: Personalized, Proactive, and Target-Driven Management
https://reachmd.com/programs/cme/ibd-care-reimagined-personalized-proactive-and-target-driven-management/54174/Explore IBD treatment selection in this comprehensive program for community gastroenterologists, with topics including therapies, targets, and emerging data.